Case report: Hemophagocytic lymphohistiocytosis in a child with primary immunodeficiency infected with Talaromyces marneffei

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening immune-mediated disease that affects patients with known genetic defects and is increasingly found among those with autoimmune diseases and persistent infections. Talaromyces marneffei (TM) is a human opportunistic fungus that commonly infects immunodeficient or immunosuppressed individuals. Few TM-associated secondary HLH cases resulting from autoimmune deficiency have been reported previously. The current case study describes a pediatric patient hospitalized with recurrent fever and lymphadenopathy. The child had abnormal blood cell classification, and microscopy revealed mature granulocytes that phagocytized fungal spores. It was speculated that the patient was infected with TM. The pathogen was detected earlier than the blood culture and confirmed by metagenomic next-generation sequencing. Whole-exome sequencing revealed that the patient had complex mutations associated with immunodeficiency. This included a mutation in exon 3 of the CD40LG gene, c.346G>A, which may be linked to hyper-IgM syndrome, a primary immunodeficiency disease with immunoglobulin conversion recombination defects that could explain the patient’s increased susceptibility to serious opportunistic infections. In addition, a heterozygous frameshift variant, c.820dup (p.Asp274GlyfsTer61), was detected in exon 6 of CARD9, a key gene associated with fungal immune surveillance. After 4 days of fungal treatment, the abnormal blood cell clusters disappeared, but other infections occurred in succession for 6 months after rehabilitation. The patient was followed with the aim of providing subsequent immunotherapy. This study found that infection can trigger HLH in HIV-negative individuals, highlighting the importance of early definitive identification of the causative agent and investigation of potential immunodeficiency.

[1]  Xiaodong Zhao,et al.  Clinical, genetic and immunological characteristics of 40 Chinese patients with CD40 ligand deficiency , 2019, Scandinavian journal of immunology.

[2]  Y. Lau,et al.  Application of Flow Cytometry in the Diagnostics Pipeline of Primary Immunodeficiencies Underlying Disseminated Talaromyces marneffei Infection in HIV-Negative Children , 2019, Front. Immunol..

[3]  Cunwei Cao,et al.  Characteristics and Prognosis of Talaromyces marneffei Infection in Non-HIV-Infected Children in Southern China , 2019, Mycopathologia.

[4]  K. Risma,et al.  Hemophagocytic Lymphohistiocytosis: Clinical Presentations and Diagnosis. , 2019, The journal of allergy and clinical immunology. In practice.

[5]  Y. Ruan,et al.  Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  H. Cao,et al.  Recurrent fungal infections in a Chinese patient with CARD9 deficiency and a review of 48 cases , 2018, The British journal of dermatology.

[7]  A. Aghamohammadi,et al.  The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management. , 2019, Clinical immunology.

[8]  M. Lionakis,et al.  Human CARD9: A Critical Molecule of Fungal Immune Surveillance , 2018, Front. Immunol..

[9]  Z. Wan,et al.  Impaired Specific Antifungal Immunity in CARD9-Deficient Patients with Phaeohyphomycosis. , 2017, The Journal of investigative dermatology.

[10]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[11]  Y. Lau,et al.  Cellular and Molecular Defects Underlying Invasive Fungal Infections—Revelations from Endemic Mycoses , 2017, Front. Immunol..

[12]  J. Farrar,et al.  A Trial of Itraconazole or Amphotericin B for HIV‐Associated Talaromycosis , 2017, The New England journal of medicine.

[13]  Zhongyuan Lin,et al.  Retrospective analysis of 15 cases of Penicillium marneffei infection in HIV-positive and HIV-negative patients. , 2017, Microbial pathogenesis.

[14]  E. Diao Clinical Presentations and Diagnosis , 2017 .

[15]  M. T. de la Morena,et al.  Clinical Phenotypes of Hyper-IgM Syndromes. , 2016 .

[16]  J. Nosanchuk,et al.  Talaromyces marneffei laccase modifies THP-1 macrophage responses , 2016, Virulence.

[17]  É. Azoulay,et al.  Diversity and combinations of infectious agents in 38 adults with an infection-triggered reactive haemophagocytic syndrome: a multicenter study. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  P. Woo,et al.  Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients , 2016, Emerging Microbes & Infections.

[19]  T. Morio,et al.  Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan. , 2015, The Journal of allergy and clinical immunology.

[20]  S. Spector,et al.  Practice parameter for the diagnosis and management of primary immunodeficiency. , 2015, The Journal of allergy and clinical immunology.

[21]  L. Santos‐Argumedo,et al.  A novel CD40LG deletion causes the hyper-IgM syndrome with normal CD40L expression in a 6-month-old child , 2015, Immunologic Research.

[22]  R. Geha,et al.  A novel disease-causing CD40L mutation reduces expression of CD40 ligand, but preserves CD40 binding capacity. , 2014, Clinical immunology.

[23]  Xiaodong Zhao,et al.  Clinical, molecular, and T cell subset analyses in a small cohort of Chinese patients with hyper-IgM syndrome type 1. , 2014, Human immunology.

[24]  Xiaolin Wang,et al.  CARD9 mutations linked to subcutaneous phaeohyphomycosis and TH17 cell deficiencies. , 2014, The Journal of allergy and clinical immunology.

[25]  Y. Lau,et al.  Penicillium marneffei infection and impaired IFN-γ immunity in humans with autosomal-dominant gain-of-phosphorylation STAT1 mutations. , 2014, The Journal of allergy and clinical immunology.

[26]  J. Verbsky,et al.  Laboratory Diagnosis of Primary Immunodeficiencies , 2014, Clinical Reviews in Allergy & Immunology.

[27]  M. Jordan,et al.  Hemophagocytic lymphohistiocytosis: updates and evolving concepts , 2012, Current opinion in pediatrics.

[28]  S. Davies,et al.  Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. , 2010, Blood.

[29]  C. Khamwan,et al.  Development of TaqMan real‐time polymerase chain reaction for the detection and identification of Penicillium marneffei , 2009, Mycoses.

[30]  P. Easterbrook,et al.  Cerebral toxoplasmosis in a middle-aged man as first presentation of primary immunodeficiency due to a hypomorphic mutation in the CD40 ligand gene , 2008, Journal of Clinical Pathology.

[31]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[32]  H. Ochs,et al.  Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. , 2005, Blood.

[33]  J. Bertin,et al.  CARD9 Is a Novel Caspase Recruitment Domain-containing Protein That Interacts With BCL10/CLAP and Activates NF-κB* , 2000, The Journal of Biological Chemistry.

[34]  C. Kinnon,et al.  Mutation analysis in CD40 ligand deficiency leading to X‐linked hypogammaglobulinemia with hyper IgM syndrome , 1996, Human mutation.